8
Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates (ADCs), which may offer a new approach to treating cancers driven by oncogenic mutations. PH1 modulates RNA splicing to induce cancer cell death and activate the immune system. It generates neoantigens through mis-spliced […]
Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates (ADCs), which may offer a new approach to treating cancers driven…